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ABSTRACT The association between Down syndrome and psoriasis is un-
clear. Immunological abnormalities that present in individuals with Down 
syndrome result in mild immune debilitation, thus the risk of infectious 
complications during immunosuppressive therapy might be higher in 
this group of patients. We present a case of 12-year-old girl with severe 
plaque psoriasis and Down syndrome, who was initially treated with cy-
closporine with good response. However, the drug was withdrawn due to 
massive viral warts development and loss of efficacy. Afterwards, the girl 
was treated with etanercept in short 10 week and long 24 week courses 
with excellent response. The presented case is the first report of a child 
with Down syndrome and concomitant severe plaque psoriasis treated 
successfully with etanercept. 
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INTRODUCTION
Down syndrome (DS) may be associated with vari-
ous skin conditions, including xerosis, alopecia areata, 
vitiligo, atopic and seborrheic dermatitis, keratoder-
mas, skin infections, and many others (1,2). Conflict-
ing data are available on the association between DS 
and plague psoriasis (PP) (1,3). Due to multiple immu-
nological abnormalities observed in individuals with 
DS which result in mild immune debilitation, the de-
cision on initiation of systemic immunosuppressive 
treatment should be made particularly carefully (4,5). 
Cases of severe PP in children with DS often consti-
tute a treatment challenge.
CASE REPORT
A 12-year-old girl with DS and severe PP refractory 
to topical agents was admitted to our Department 
2.5 years ago. The first PP skin lesions had appeared 
when she was 4 years old. At the time of admission to 
our institution, almost the whole body surface was af-
fected with psoriatic plagues (psoriasis area severity 
index (PASI) score: 41, body surface area (BSA): 78%; 
Figure 1). Because the patient’s skin lesions usually 
worsened after sun exposure, phototherapy was not 
considered as a treatment option. During the first hos-
pitalization in our Clinic, therapy with cyclosporine A 
(CsA) was initiated (3.5 mg/kg/d, P.O.), with marked 
improvement observed two weeks later. However, 
the dose was tapered to 1.7 mg/kg/d because of el-
evated liver enzymes. During the next 6 months, we 
achieved almost complete remission of PP, with only 
occasional appearances of mild psoriatic lesions on 
the elbows and dorsal surfaces of the hands. We later 
observed the appearance of multiple viral warts on 
the fingers, so CsA was withdrawn and topical treat-
ment with 5-fluorouracil and salicylic acid was initiat-
ed, with the subsequent disappearance of warts. Due 
to PP relapse observed 3 weeks after discontinuation 
of CsA, the therapy was initiated again (1.7 mg/kg/d) 
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with satisfactory, but not complete improvement. Un-
fortunately, 8 months later we observed a severe flare 
of PP, mostly on sun-exposed areas (PASI: 12.7, BSA: 
15.5%; Figure 2). CsA was withdrawn, and etanercept 
(ETN) 0.8 mg/kg was administered subcutaneously 
every week. A rapid improvement was seen as soon as 
1 week after the first injection, and almost complete 
remission was achieved during the following weeks, 
with only residual scaling observed on the lower legs 
and forearms (PASI: 2.0, BSA: 5.5% at week 8; Figure 
3). Unfortunately, we had to stop therapy 10 weeks 
later because of the lack of refunding possibilities. 
After ETN discontinuation, we observed a long-term 
alleviation of PP, and the skin lesions were controlled 
well with topical agents over the next 8 months. Since 
then, 2 severe exacerbations of PP occurred, both af-
ter sun exposure in the summer months, which were 
completely alleviated by 24-week courses of ETN. 
DISCUSSION
The association between PP and DS is unclear. 
Quite recently, it was suggested that a dysregula-
tion of the interferon-γ system is responsible for sus-
ceptibility to PP in the DS population (6). Moreover, 
Figure 1. Extensive psoriatic lesions covering most of the 
body surface. 
Figure 2. Exacerbation of skin lesions during treatment with cyclosporine. 
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immunological alterations, including reduction in 
B lymphocytes and CD4(+) T-cells, the increase in 
CD8(+) T-cells, and expansion of natural killer (NK) 
cells result in increased susceptibility to infections 
and malignancies in this group of patients (4,5). Thus, 
a higher risk of infectious complications during im-
munosuppressive treatment is expected and requires 
special care inmaking therapeutic decisions. 
Approximately 30% of all patients with PP experi-
ence the onset of the disease before 16 years of age 
(7). The management of PP in children includes topi-
cal agents in mild and moderate cases and systemic 
immunomodulatory agents in more severe cases; 
however, standardized guidelines are lacking (8). 
Methotrexate (MTX), CsA, and acitretin can be used in 
justified cases after taking several issues into consid-
eration, such as the severity of disease, psychological 
burden, comorbidities, patient age, etc. (8). Few re-
ports of patients with severe PP and DS treated with 
systemic agents are available.  
Biologic drugs, which target proteins, cells, and 
pathways responsible for the development of inflam-
matory cascade, are considered less immunosuppres-
sive than conventional systemic therapies. They thus 
represent a promising therapeutic option for children 
affected with psoriasis and in DS patients. Among bi-
ologic agents, the efficacy and safety of ETN is best 
documented for the treatment of childhood PP with 
randomized controlled trial with an open-label ex-
tension (9,10). ETN was approved by the European 
Medicines Agency for the treatment of severe PP in 
children >6 years old in 2009 in intermittent, 24-week 
treatment courses (8). Notably, 70% of participants in 
a European expert group consensus consider ETN as 
the first-line treatment option for juvenile chronic PP 
due to its good efficacy, tolerability, and safety pro-
files (11). Potential side-effects are rare and include 
higher risk of infections, injection-site reactions, ana-
phylaxis, development of anti-nuclear antibodies, lu-
pus-like syndrome, and pancytopenia (8).
Only anecdotal data were published concerning 
the biologic treatment of psoriasis in patients with 
DS, with one case report of a child treated with adali-
mumab (Table 1). In our patient, therapeutic doses 
of CsA were hepatotoxic, and the therapy was com-
plicated by viral warts. ETN was well tolerated and 
effective despite long treatment intervals. To our 
knowledge, this is the first case of a child with severe 
PP and DS successfully treated with ETN. We suggest 
considering biologic therapy, including ETN, as a first-
line systemic treatment in children with DS and se-
vere PP. 
Demographic data Failed systemic treatments Successful treatment
20-year-old man (6) etanercept 50 mg/week + methotrexate 
15 mg/week
adalimumab 40 mg S.C. every other week + 
methotrexate 15 mg/week
12-year old boy (6) - adalimumab 40 mg S.C. every other week
30-year-old man (12) topical agents; cyclosporine, 
methotrexate- contraindicated
etanercept 25 mg S.C. twice a week
31-year-old man (13) anti- tumor necrosis factor agents ustekinumab 45 mg S.C. initially and 4 weeks 
later, followed by 45 mg every 12 weeks
Table 1. Characteristics of patients with Down syndrome and plaque psoriasis treated with biologic 
agents (references in brackets)
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Figure 3. Resolution of psoriasis after treatment with etan-
ercept. 
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